ATE71627T1 - Bryostatine. - Google Patents

Bryostatine.

Info

Publication number
ATE71627T1
ATE71627T1 AT87306552T AT87306552T ATE71627T1 AT E71627 T1 ATE71627 T1 AT E71627T1 AT 87306552 T AT87306552 T AT 87306552T AT 87306552 T AT87306552 T AT 87306552T AT E71627 T1 ATE71627 T1 AT E71627T1
Authority
AT
Austria
Prior art keywords
bryostatin
bryostatins
linneaeus
bryozoan
phylum
Prior art date
Application number
AT87306552T
Other languages
English (en)
Inventor
George R Pettit
Cherry L Herald
Yoshiaki Kamano
John E Leet
Original Assignee
Univ Arizona State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona State filed Critical Univ Arizona State
Application granted granted Critical
Publication of ATE71627T1 publication Critical patent/ATE71627T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Vending Machines For Individual Products (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT87306552T 1986-07-28 1987-07-24 Bryostatine. ATE71627T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/889,946 US4833257A (en) 1986-07-28 1986-07-28 Compositions of matter and methods of using same
EP87306552A EP0264173B1 (de) 1986-07-28 1987-07-24 Bryostatine

Publications (1)

Publication Number Publication Date
ATE71627T1 true ATE71627T1 (de) 1992-02-15

Family

ID=25396026

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87306552T ATE71627T1 (de) 1986-07-28 1987-07-24 Bryostatine.

Country Status (8)

Country Link
US (1) US4833257A (de)
EP (1) EP0264173B1 (de)
JP (1) JP2626889B2 (de)
AT (1) ATE71627T1 (de)
CA (1) CA1305476C (de)
DE (1) DE3776063D1 (de)
ES (1) ES2038664T3 (de)
GR (1) GR3004061T3 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256646A (en) * 1990-07-27 1993-10-26 Bristol-Myers Squibb Company Antiviral antibiotic BU-4224V
US5072004A (en) * 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5196447A (en) * 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
US5436400A (en) * 1993-01-19 1995-07-25 Arizona Board Of Regents Isolation and structure of spongistatin 1
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5684036A (en) * 1994-02-18 1997-11-04 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
US5478861A (en) * 1994-02-18 1995-12-26 Harbor Branch Oceanographic Institution, Inc. Cytotoxic macrolides and methods of use
AU2337997A (en) * 1996-03-20 1997-10-10 Arizona Board Of Regents, The Method of treating cancer using c-26 modified bryostatin
US7256286B2 (en) * 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US6624189B2 (en) 1999-11-30 2003-09-23 The Board Of Trustees Of The Leland Stanford Junior University Byrostatin analogues, synthetic methods and uses
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US7402571B2 (en) * 2000-07-31 2008-07-22 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
EP1383497B1 (de) * 2001-05-02 2008-10-15 Blanchette Rockefeller Neurosciences Institute Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6900339B2 (en) 2002-04-30 2005-05-31 The University Of North Carolina At Chapel Hill Bryostatin composition and bryostatin acquisition methodologies
EP1511477A4 (de) * 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc Histondeacetylase-hemmer auf basis von alpha-ketoepoxid-verbindungen
CN1678304B (zh) * 2002-07-02 2012-06-27 布朗歇特洛克菲勒神经科学研究所 苔藓抑制素类化合物在制备用于活化PKC而增强sAPPα分泌和改善认知的药物中的应用
WO2004046104A2 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
CA2535029C (en) * 2003-08-07 2013-07-16 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
EP1817020A4 (de) * 2004-11-08 2012-11-21 Errant Gene Therapeutics Inc Inhibitoren der histondeacetylase
CA2617003A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
EP2452691A3 (de) * 2005-08-29 2012-09-05 HealOr Ltd. Verfahren und Zusammensetzungen zur Vorbeugung von diabetischer und alternder Haut
EP2073801A1 (de) 2006-07-28 2009-07-01 Blanchette Rockefeller Neurosciences Institute Verfahren zur stimulierung des zellwachstums, der synaptischen remodellierung und der konsolidierung des langzeitgedächtnisses
CA3006091A1 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
EP2121000B1 (de) 2007-02-09 2015-09-23 Blanchette Rockefeller Neurosciences, Institute Therapeutische wirkungen von bryostatinen, bryologen und anderen damit zusammenhängenden substanzen auf durch kopftraumata herbeigeführte gedächtnisstörungen und hirnverletzungen
KR20130121678A (ko) * 2007-07-30 2013-11-06 힐로 리미티드 약제학적 조성물 및 관련 방법
CN102325789A (zh) * 2009-02-24 2012-01-18 希尔洛有限公司 用于治疗痤疮和其它病症的内脂素治疗药物
CA2789972A1 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
JP6446624B2 (ja) 2010-07-08 2019-01-09 アルコン、ダニエル・エル. 脳卒中の治療法におけるpkc活性化因子および抗凝血剤
EP2605773A1 (de) 2010-08-19 2013-06-26 Blanchette Rockefeller Neurosciences, Institute Behandlung von kognitiven störungen im zusammenhang mit abnormalen dendritischen spikes anhand von pkc-aktivatoren
EP3967299A1 (de) 2011-11-13 2022-03-16 Cognitive Research Enterprises, Inc. Pkc-aktivatoren und kombinationen davon
EP2925315B1 (de) * 2012-11-27 2019-01-16 Aphios Corporation Bryoidzusammensetzungen, verfahren zur herstellung und verwendung davon
WO2016130969A1 (en) 2015-02-13 2016-08-18 George Robert Pettit Silstatin compounds
WO2016183252A1 (en) 2015-05-11 2016-11-17 Alkon, Daniel, L. Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
WO2019094709A1 (en) 2017-11-09 2019-05-16 Pettit George R Betulastatin compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
JPS60174418A (ja) * 1984-02-18 1985-09-07 Ishikawajima Harima Heavy Ind Co Ltd 下水あるいはし尿汚泥等の流動層式焼却装置
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8

Also Published As

Publication number Publication date
JPS63183585A (ja) 1988-07-28
EP0264173A3 (en) 1988-07-13
EP0264173A2 (de) 1988-04-20
GR3004061T3 (de) 1993-03-31
JP2626889B2 (ja) 1997-07-02
ES2038664T3 (es) 1993-08-01
CA1305476C (en) 1992-07-21
US4833257A (en) 1989-05-23
DE3776063D1 (en) 1992-02-27
EP0264173B1 (de) 1992-01-15

Similar Documents

Publication Publication Date Title
ATE71627T1 (de) Bryostatine.
DK172089D0 (da) 1,3-dioxolanderivater samt fremgangsmaade til fremstilling deraf
NO20004978L (no) Semi-syntetiske ecteinascidiner
FI930977A0 (fi) Taxanderivat, deras framstaellning och onkologiska anvaendning
MC1772A1 (fr) Derives de la quinoleine
ES544752A0 (es) Un procedimiento para la preparacion de carbapenems.
GR1000156B (el) ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΝΕΩΝ ΠΑΡΑΓΩΓΩΝ ΤΡΙΚΥΚΛΙΚΩΝ ΑΜΙΝΩΝ ΤΗΣ ΤΕΤΡΑΥΔΡΟ-5,6,7,8ΝΑΦΘΟ[2,3b] ΔΙΥΔΡΟ-2,3 ΦΟΥΡΑΝΗΣ & ΤΗΣ ΤΕΤΡΑΥΔΡΟ-6,7,8,9 5Η-ΒΕΝΖΟΚΥΚΛΟΕΠΤΑ[2,3Β] ΔΙΥΔΡΟ-2,3 ΦΟΥΡΑΝΗΣ.
ES544753A0 (es) Un procedimiento para la preparacion de carbapenems.
DE3777590D1 (de) 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8-inter-m-phenylene-pgi2-derivate.
WO1988003922A3 (en) Thiophenesulfonamide herbicides
FI903779A0 (fi) S-substituerade betatioacrylamider och deras anvaendning som mikrobicider.
FI934468A0 (fi) Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytesmellanprodukter
ES2079724T3 (es) Nuevos compuestos antibioticos y su produccion.
FR2597105B1 (fr) Derives antibiotiques de la famille des 20-0-acyl-19,20-enolmacrolides
OA09221A (fr) "Synthèse asymétrique des dérivés de la furo (3, 4-c) pyridine".
FI873000A0 (fi) Substituoituja 1,2,3-tiadiatsoli-4-tiolaatteja
AR241135A2 (es) "derivados de n-triazinil-n-sulfamoilurea herbicidamente activos y formulacion herbicida que los contiene".
ES2039270T3 (es) Derivados de gamma-l-glutamil-4-nitroanilida y procedimiento para determinar actividad de gamma-gtp utilizandolos.
SU1417444A1 (ru) 2,4-Дифенил-3(4-ацетокси-4-метилгексин-2-ил)-3-азабицикло [3,3,1]нонан-9-он, проявляющий противовоспалительную активность

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee